PowerUp Acquisition enters additional Non-Redemption Agreements covering 750,000 shares for extension vote

Aspire Biopharma Holdings, Inc.

Five additional Non-Redemption Agreements with unaffiliated third parties covering 750,000 Class A ordinary shares.
Sponsor to transfer 375,000 Class B ordinary shares to investors post-business combination if shares held through meeting.
Agreements increase funds remaining in trust after extraordinary general meeting to approve extension to May 23, 2024.
Total non-redeemed shares now 900,000 (previous 150,000 + 750,000) under all Non-Redemption Agreements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.